Hoth Therapeutics said that a preclinical study conducted at North Carolina State University demonstrated that the company’s HT-004 inhaled antisense oligonucleotide significantly reduced lung inflammation in mice following an ovalalbumin challenge. According to Hoth, HT-004 works “to eliminate cell surface high-affinity IgE receptor (FceRI) expression and function on mast cells and basophils, rendering mast cells unresponsive to IgE-mediated activation that occurs during asthma and allergy disorders.”
Hoth said that inhaled HT-004 reduced bronchiolar inflammation in treated mice to a level near that of mice that were not challenged with ovalalbumin and that the results “support the use of HT-004 as a novel inhalation maintenance therapy for asthma and allergic disorders.” The company said that it now intends to conduct studies in larger animals.
Read the Hoth Therapeutics press release.
